PMID- 27112612
OWN - NLM
STAT- MEDLINE
DCOM- 20170126
LR  - 20181202
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 44
IP  - 4
DP  - 2016 Apr 24
TI  - [Efficacy of biventricular pacing on preventing heart failure in patients with 
      high degree atrioventricular block (BIVPACE-AVB Trial)].
PG  - 331-7
LID - 10.3760/cma.j.issn.0253-3758.2016.04.011 [doi]
AB  - OBJECTIVE: To investigate the long-term effect of biventricular (BIV) and right 
      ventricular apical (RVA) pacing on cardiac function in patients with high-degree 
      atrioventricular block (AVB) and left ventricular ejection fraction(LVEF)over 
      35%. METHODS: A total of 118 consecutive patients with high-degree AVB in six 
      hospitals from East China between May 2009 and December 2012 were enrolled in 
      this randomized, double-blind and parallel controlled study. Patients were 
      randomly assigned to BIV and RVA pacing with or without LV lead on after one-week 
      cardiac resynchronization therapy (CRT). Cardiac function including New York 
      Heart Association(NYHA), 6 minute walking distance (6MWD), Minnesota living with 
      heart failure (MLHF) score, LVEF, left ventricular end-diastolic 
      volumes/diameters (LVEDV/LVEDD) and other echocardiography parameters, as well as 
      N-terminal pro-B-type natriuretic peptide (NT-proBNP)were assessed at 6 months 
      and 12 months. RESULTS: A total of 114 patients were successfully implanted with 
      CRT. Cardiac function was significantly improved after one-week BIV pacing (n=57) 
      compared with pre-CRT: rate of patients with NYHA Ⅲ (25.44%(29/114) vs. 
      9.65%(11/114)), MLHF score (17.1+/-13.6 vs. 26.9+/-21.6), 6MWD ((315.4+/-121.8)m vs. 
      (291.8+/-102.9)m) and NT-proBNP (157.0(70.0, 639.0) ng/L vs. 444.7(144.0, 1 
      546.0)ng/L, all P<0.05). In BIV group, 6MWD extended from (314.8+/-142.7)m to 
      (332.7+/-117.5)m at 6 months (P<0.05), LVEF increased from (60.7+/-7.9)% at 1 week to 
      (56.6+/-10.7)% at 6 months(P<0.05), both LVEDV and LVEDD decreased at 12 months 
      compared with at 1 week ((116.2+/-39.5)ml vs. (131.4+/-49.6)ml and (50.2+/-5.6)mm vs. 
      (52.5+/-6.8)mm, P<0.05). In RVA group (n=57), 6MWD increased at 6 months compared 
      that at 1week ((342.4+/-109.9)m vs. (310.2+/-105.1)m, P<0.05), NT-proBNP was higher 
      at 12 months than that at 1 week (349.5(191.8, 884.3)ng/L vs. 127.0(70.3, 
      336.7)ng/L, P<0.05). Compared with RVA group, BIV group had a bigger shrink in 
      LVEDV decrease at 12 months was more significant in BIV group ((-16.68+/-24.30)ml 
      vs. (9.09+/-29.30)ml, P<0.05). CONCLUSIONS: Cardiac pacing could acutely improve 
      the cardiac function in patients with high-degree AVB and LVEF over 35%. 
      Improvements on cardiac function and remodeling are more significant after 
      12-month BIV pacing than that of RVA pacing. Clinical Trail Registry: Chinese 
      Clinical Trial Registry, ChiCTR-TRC-10000832.
FAU - Zhang, X Y
AU  - Zhang XY
AD  - Department of Cardiology, First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Shan, Q J
AU  - Shan QJ
FAU - Su, Y G
AU  - Su YG
FAU - Yan, J
AU  - Yan J
FAU - Bao, Z H
AU  - Bao ZH
FAU - Gu, X
AU  - Gu X
FAU - Qiu, J P
AU  - Qiu JP
FAU - Qin, S M
AU  - Qin SM
FAU - Xu, J
AU  - Xu J
FAU - Su, H
AU  - Su H
FAU - Zhu, H
AU  - Zhu H
FAU - Guo, J F
AU  - Guo JF
FAU - Lu, J P
AU  - Lu JP
FAU - Zou, J G
AU  - Zou JG
FAU - Chen, M L
AU  - Chen ML
FAU - Xu, D
AU  - Xu D
FAU - Cao, K J
AU  - Cao KJ
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Atrioventricular Block/*physiopathology
MH  - Cardiac Resynchronization Therapy/*methods
MH  - China
MH  - Double-Blind Method
MH  - Echocardiography
MH  - Heart Failure/*prevention & control
MH  - Heart Ventricles
MH  - Humans
MH  - Natriuretic Peptide, Brain/metabolism
MH  - Peptide Fragments/metabolism
MH  - Stroke Volume
MH  - Treatment Outcome
MH  - Ventricular Function, Left
EDAT- 2016/04/27 06:00
MHDA- 2017/01/27 06:00
CRDT- 2016/04/27 06:00
PHST- 2016/04/27 06:00 [entrez]
PHST- 2016/04/27 06:00 [pubmed]
PHST- 2017/01/27 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-3758.2016.04.011 [doi]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Apr 24;44(4):331-7. doi: 
      10.3760/cma.j.issn.0253-3758.2016.04.011.